Abstract: Disclosed is a method for determining one or more tractor units for a tractor-trailer in a system including a plurality of electrically driven tractor units. Each tractor unit is configured to form a tractor-trailer with a respective trailer and to tow the respective trailer. The method includes: receiving a first item of transport order information, representing a loading position and an unloading position, receiving first items of tractor unit information representing a current position of the respective tractor unit and an estimated current range of the respective tractor unit, determining the first tractor unit in order to form a first tractor-trailer for transporting the goods along a first section of a transport route, the determination of the first tractor unit being performed while considering the first item of transport order information and the first items of tractor unit information.

Abstract: A pharmaceutical composition as a solid oral dosage form is described, comprising: i) a combination of two pharmacological active principles, dexketoprofen salt with an organic or inorganic base and tramadol salt with an organic or inorganic acid, wherein: the organic or inorganic base is selected in the group: trometamol, trimethylamine, dimethylamine, ethylamine, triethylamine, diethylamine, L-lysine, L-arginine, diethanolamine, sodium hydroxide, calcium hydroxide the organic or inorganic acid is selected in the group: hydrochloric, hydrobromic, phosphoric, sulfuric, methanesulfonic, benzenesulfonic, toluenesulfonic, acetic, propionic, malic, maleic, succinic, citric, L-tartaric, lactic, malonic, aspartic, glutamic; ii) microcrystalline cellulose as a filler; iii) a binder selected in the group: maize starch, pre-gelatinized maize starch, hypromellose or their mixtures; iv) pharmaceutically acceptable excipients.

Abstract: Oral liquid pharmaceutical compositions containing as active ingredient Nepadutant, PGS as solubilizer and optionally a chelating agent. Such compositions are found to be very stable and suitable for paediatric use in the treatment of gastro-intestinal diseases.

Abstract: A pharmaceutical composition as a solid oral dosage form is described, comprising: i) a combination of two pharmacological active principles, dexketoprofen salt with an organic or inorganic base and tramadol salt with an organic or inorganic acid, wherein: the organic or inorganic base is selected in the group: trometamol, trimethylamine, dimethylamine, ethylamine, triethylamine, diethylamine, L-lysine, L-arginine, diethanolamine, sodium hydroxide, calcium hydroxide the organic or inorganic acid is selected in the group: hydrochloric, hydrobromic, phosphoric, sulfuric, methanesulfonic, benzenesulfonic, toluenesulfonic, acetic, propionic, malic, maleic, succinic, citric, L-tartaric, lactic, malonic, aspartic, glutamic; ii) microcrystalline cellulose as a filler; iii) a binder selected in the group: maize starch, pre-gelatinised maize starch, hypromellose or their mixtures; iv) pharmaceutically acceptable excipients.

Abstract: Oral liquid pharmaceutical compositions containing as active ingredient Nepadutant, PGS as solubilizer and optionally a chelating agent. Such compositions are found to be very stable and suitable for paediatric use in the treatment of gastro-intestinal diseases.

Abstract: The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative.

Abstract: The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative.

Abstract: Ophthalmic composition containing brivudine as active ingredient and a film-forming agent selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and polyacrylate (PA).

Abstract: Topical formulations containing the virustatic agent brivudine and stabilizers useful to present its photodegradation are disclosed.

Abstract: There is disclosed the use of metal-oxides pigments as photodegradation stabilizers in topical compositions containing brivudine.

Abstract: The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter ≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surfactant (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.

Abstract: The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter≦8 &mgr;m.

Abstract: The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surface-active substance (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.